Nanotechnology Now - Press Release: Abraxis BioScience to Present at 28th Annual J.P. Morgan Healthcare Conference

Home > Press > Abraxis BioScience to Present at 28th Annual J.P. Morgan Healthcare Conference

Abstract:
J.P. Morgan 28th Annual Healthcare Conference 2010

Abraxis BioScience to Present at 28th Annual J.P. Morgan Healthcare Conference

Los Angeles, CA | Posted on January 8th, 2010

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced today that Lonnie Moulder, the company's president and chief executive officer, will present a company update at the 28th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2010 at 4:00 p.m. Pacific time. The conference is being held at the Westin St. Francis in San Francisco.

A live webcast of the presentation will be available in the Investor Relations section of the company's Web site at www.abraxisbio.com, as well as www.events.jpmorgan.com. The webcast will be archived and accessible on the company's Web site for at least 14 days.

####

About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 38 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.

For more information, please click here

Contacts:
Investor & Media Inquiries
Abraxis BioScience, Inc.
Maili Bergman
Director Investor Relations & Corporate Communications
310-883-1300

or
PondelWilkinson Inc.
Rob Whetston, 310-279-5963

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: